Exosome Diagnostic and Therapeutic Market Strong Growth at a CAGR of 29.4% and Revenue to Hit USD 2.9 Bn by 2030

According to a new Allied Market Research Reports study, the global exosome diagnostic and therapeutic industry was estimated at $224.34 million in 2020, and is anticipated to hit $2.9 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.

Key Takeaways:

Exosomes are tiny vesicles that are secreted by cells and carry information between cells. They can be found in many different bodily fluids, including blood, urine, and cerebrospinal fluid.

The exosome diagnostic market is expected to grow significantly in the coming years due to the increasing demand for non-invasive diagnostic tools and the ability of exosomes to provide valuable information about a wide range of diseases.

Exosome-based diagnostics have the potential to revolutionize cancer detection and monitoring, as they can provide more accurate and reliable results than traditional methods such as biopsy.

Exosome-based therapeutics are also a promising area of research, with potential applications in cancer, neurodegenerative diseases, and regenerative medicine.

Several companies are already developing exosome-based diagnostic and therapeutic products, and collaborations between academic researchers and industry players are also driving progress in the field.

Request Sample Copy of the Report:

https://www.alliedmarketresearch.com/request-sample/1723

Market Drivers:

Non-invasive testing: Exosome-based diagnostics offer a non-invasive alternative to traditional methods such as biopsy, which can be painful and risky for patients.

Early detection and monitoring: Exosomes can provide valuable information about diseases at an early stage, allowing for earlier diagnosis and better monitoring of disease progression.

Accuracy and specificity: Exosome-based diagnostics can provide more accurate and specific results compared to traditional diagnostic methods, especially for diseases such as cancer.

Growing prevalence of diseases: The prevalence of diseases such as cancer, neurodegenerative diseases, and infectious diseases is increasing globally, driving the demand for more effective diagnostic tools.

Technological advancements: Advances in technology have enabled the isolation, purification, and analysis of exosomes, making them more accessible as a diagnostic tool.

Support from funding agencies: Governments and funding agencies are investing in research on exosomes and their potential as diagnostic tools, driving innovation and progress in the field.

Market Segmentation:

Allied Market Research Reports has analyzed global AI in Genomics market from six perspectives: Component, Technology, Functionality, Application, End User, and Region.

Product type: This includes exosome isolation kits, exosome detection reagents, and exosome-based diagnostics and therapeutics.

Application: This includes cancer, neurodegenerative diseases, cardiovascular diseases, infectious diseases, and others.

End user: This includes hospitals and clinics, research laboratories, pharmaceutical and biotechnology companies, and others.

Source: This includes exosomes derived from urine, blood, saliva, and other bodily fluids.

Geography: This includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Type of diagnostic test: This includes liquid biopsy tests, tissue biopsy tests, and other diagnostic tests.

Request for Customization:

https://www.alliedmarketresearch.com/request-for-customization/1723

Regional Growth Dynamics:

North America held the major share in 2020, generating nearly two-fifths of the global exosome diagnostic and therapeutic market, due to rise in product launches for exosome therapeutics, surge in the presence of key players, and development of R&D activities in the pharmaceutical and biopharmaceutical sector across the province. Asia-Pacific, however, would grow at the fastest CAGR of 30.3% by 2030. Increase in the prevalence of chronic and infectious disorders, growth in health care expenditures, and surge in demand for molecular diagnosis drive the market growth in the region.

Competitive Landscape:

• Thermo Fisher Scientific Inc.
• System Biosciences LLC
• QIAGEN N.V.
• Norgen Biotek Corp.
• NanoString Technologies, Inc.
• Malvern Panalytical Ltd.
• HansaBioMed Life Sciences Ltd.
• Evomic Science LLC
• Evox Therapeutics Ltd.
• Exosome Diagnostics, Inc.

Recent developments:

In March 2021, Codiak Biosciences announced positive results from a Phase 1 clinical trial of its exosome-based cancer therapy, which demonstrated safety and efficacy in patients with advanced solid tumors.

In January 2021, Aethlon Medical announced the development of an exosome-based diagnostic test for COVID-19, which is designed to detect the presence of the virus in blood samples.

In November 2020, Evox Therapeutics announced a collaboration with Takeda Pharmaceuticals to develop exosome-based therapies for the treatment of rare diseases.

Buy this Premium Research Report:

https://www.alliedmarketresearch.com/purchase-enquiry/1723

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst

Browse more latest healthcare reports:

Cancer Diagnostics Market by Product (Consumables and Instruments), Application (Breast Cancer, Breast Cancer, Lung Cancer, Blood Cancer, Colorectal Cancer, Skin Cancer, Ovarian Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Cervical Cancer, and Others), and End Use (Hospitals & Clinics, Diagnostic Laboratories, Diagnostic Centers, and Research Institutes): Opportunity Analysis and Industry Forecast, 2021-2028

Downstream Processing Market By Technology (Purification, Separation, Clarification/Concentration), By Product (Chromatography Columns and Resins, Filters, Membrane Adsorbers, Other Products), By System (Single Use System, Re Usable System), By Application (Monoclonal Antibody Production, Vaccine Production, Insulin Production, Immunoglobulin Production, Erythropoietin Production, Other Applications), By End User (Biopharmaceutical Manufacturers, Contract Manufacturing Organizations (CMOs)): Global Opportunity Analysis and Industry Forecast, 2020-2030

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.